Download WuXi AppTec, Inc.

WuXi AppTec, Inc.
Drug Discovery  Drug Development  Biopharmaceuticals
DELEGATE(S)
Gonghua Pan
288 Fute Zhong Road, Waigaoqiao
Free Trade Zone
200131 Shanghai
China
www.wuxiapptec.com
Incorporated: 2000
Employees:
5000
Ownership:
Public
New York Stock Exchange: WX
HIGHLIGHTS
Recent
Upcoming
02/23/2010: WuXi PharmaTech Passes
EMEA Inspection of Its GMP Manufacturing
and Analytical Testing Facilities in
Shanghai.
Shanghai, August 23,2011: PRNewswireAsia — WuXi AppTec Bioanalytical Services
(BAS) unit had received a certificate of Good
Laboratory
12/22/2009: WuXi PharmaTech Included
in the Deloitte Technology Fast 500 Asia
Pacific 2009 List for the Sixth Consecutive
Year
Practice (GLP) from the Organization for
Economic Cooperation and Development
(OECD) and EU.
In 2009, WuXi received many outstanding
service awards from its biotech and
pharma partners such as Schering-Plough,
Eli Lilly, BASF, Astrazeneca.
06/16/2011: WuXi AppTec Named a Top
Ten Chinese Outsourcing Enterprise —
Dr. Ge Li, Chairman and CEO, Named a Top
Ten Contributor to China's Outsourcing
Industry.
MISSION/BACKGROUND
WuXi AppTec is a leading global pharmaceutical, biologics, and medical device outsourcing company with operations in China and the
US. We provide laboratory and manufacturing services from discovery to commercialization – helping shorten time to market and
lower the cost of R&D.
Our GMP and GLP facilities in China and the US (>2 million sq. ft.) are recognized by worldwide regulatory authorities (FDA, EMA, TGA,
sFDA, KFDA, JMHLW and OECD). WuXi AppTec is listed (WX) on the NYSE with a market cap of >$1 billion USD.

Biopharmaceutical Testing: GLP/GMP-compliant testing services for biologics. include cell line characterization, viral
clearance validation, lot release, & stability studies.

Pharmaceutical Discovery & Development: Fully integrated discovery and development programs including chemistry,
biology, ADME, DMPK, pharmacology & safety. More than 50 programs have been completed from discovery to
manufacturing in as little as 2.5 years.

Toxicology: Suzhou GLP facility is the only lab in China with dual certification from OECD & sFDA. US GLP center specializes in
medical devices, and gene & cell therapeutic biodistribution studies. All toxicology facilities are AAALAC accredited.

Bioanalytical: FDA-inspected laboratory in China has analyzed more than 500,000 clinical samples. Recently opened
bioanalytical lab in the US.

Pharmaceutical and Biologics GMP Manufacturing: Pharmaceutical CMC services for intermediates & APIs, delivering more
than 120 APIs & 160 Clinical Trial batches. GMP manufacturing is available for cell therapy & tissue-based products. More
than 1,000 GMP lots have been produced.

Combination Products: Unique experience to support companies developing combination products (drug-coated stents,
tissue-based products used for wound healing, etc.) requiring expertise and understanding of the regulatory requirements
involving multiple regulatory agency approval, (e.g., US FDA CBER/CDRH or CDER /CDRH).
ALLIANCES
Below are several recent announced collaborations for public release. Other collaborations are ongoing or not publicly announced yet.
NEW YORK and SHANGHAI, March 7, 2011: Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical
and Stability Testing Facility.
March 2010: WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and
Training.
December 2009: WuXi PharmaTech Selects Labcyte POD™ 810 Platform for High-Throughput Screening.
In-Vitro ADME Collaboration with Pfizer through 2011.
Integrated Pharmaceutical Research and Dev. collaboration with Johnson & Johnson Pharmaceutical R&D (J&JPRD) for discovery
chemistry, discovery biology, chemical and analytical development.
Profiles – 105